These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 36352098)

  • 21. Targeted delivery in scleroderma fibrosis.
    Varrica C; Dias HS; Reis C; Carvalheiro M; Simões S
    Autoimmun Rev; 2021 Feb; 20(2):102730. PubMed ID: 33338593
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis.
    MacDonald KG; Dawson NAJ; Huang Q; Dunne JV; Levings MK; Broady R
    J Allergy Clin Immunol; 2015 Apr; 135(4):946-955.e9. PubMed ID: 25678090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MicroRNAs: their involvement in fibrosis pathogenesis and use as diagnostic biomarkers in scleroderma.
    Zhu H; Luo H; Zuo X
    Exp Mol Med; 2013 Sep; 45(9):e41. PubMed ID: 24052166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrosis and immune dysregulation in systemic sclerosis.
    Chizzolini C; Brembilla NC; Montanari E; Truchetet ME
    Autoimmun Rev; 2011 Mar; 10(5):276-81. PubMed ID: 20863906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular Basis of Accelerated Aging with Immune Dysfunction-Mediated Inflammation (Inflamm-Aging) in Patients with Systemic Sclerosis.
    Shen CY; Lu CH; Wu CH; Li KJ; Kuo YM; Hsieh SC; Yu CL
    Cells; 2021 Dec; 10(12):. PubMed ID: 34943909
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokines Involved in the Pathogenesis of SSc and Problems in the Development of Anti-Cytokine Therapy.
    Shima Y
    Cells; 2021 May; 10(5):. PubMed ID: 34064515
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The lung megakaryocytes and pulmonary fibrosis in systemic sclerosis.
    Thachil J
    Med Hypotheses; 2009 Mar; 72(3):291-3. PubMed ID: 19036527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of a humanized animal model of systemic sclerosis in which T helper-17 cells from patients with systemic sclerosis infiltrate and cause fibrosis in the lungs and skin.
    Park MJ; Park Y; Choi JW; Baek JA; Jeong HY; Na HS; Moon YM; Cho ML; Park SH
    Exp Mol Med; 2022 Sep; 54(9):1577-1585. PubMed ID: 36175484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type 2 innate lymphoid cell counts are increased in patients with systemic sclerosis and correlate with the extent of fibrosis.
    Wohlfahrt T; Usherenko S; Englbrecht M; Dees C; Weber S; Beyer C; Gelse K; Distler O; Schett G; Distler JH; Ramming A
    Ann Rheum Dis; 2016 Mar; 75(3):623-6. PubMed ID: 26338035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature.
    Giuggioli D; Lumetti F; Colaci M; Fallahi P; Antonelli A; Ferri C
    Autoimmun Rev; 2015 Nov; 14(11):1072-8. PubMed ID: 26209905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oxidative stress in the pathogenesis of systemic scleroderma: An overview.
    Vona R; Giovannetti A; Gambardella L; Malorni W; Pietraforte D; Straface E
    J Cell Mol Med; 2018 Jul; 22(7):3308-3314. PubMed ID: 29664231
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathogenic Roles of Autoantibodies and Aberrant Epigenetic Regulation of Immune and Connective Tissue Cells in the Tissue Fibrosis of Patients with Systemic Sclerosis.
    Tsai CY; Hsieh SC; Wu TH; Li KJ; Shen CY; Liao HT; Wu CH; Kuo YM; Lu CS; Yu CL
    Int J Mol Sci; 2020 Apr; 21(9):. PubMed ID: 32349208
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New developments in the pathogenesis of systemic sclerosis.
    Sakkas LI
    Autoimmunity; 2005 Mar; 38(2):113-6. PubMed ID: 16040330
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [A Uuifying hypothesis for the pathogenesis of systemic sclerosis based on the deficiency of transcription factor Fli1 - the development of a new animal model of systemic sclerosis -].
    Asano Y
    Nihon Rinsho Meneki Gakkai Kaishi; 2014; 37(6):475-87. PubMed ID: 25748132
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T cell abnormalities in systemic sclerosis with a focus on Th17 cells.
    Brembilla NC; Chizzolini C
    Eur Cytokine Netw; 2012; 23(4):128-39. PubMed ID: 23360781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fresh Insights into Disease Etiology and the Role of Microbial Pathogens.
    Farina A; Farina GA
    Curr Rheumatol Rep; 2016 Jan; 18(1):1. PubMed ID: 26700911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-4 and interleukin-13 as possible therapeutic targets in systemic sclerosis.
    Gasparini G; Cozzani E; Parodi A
    Cytokine; 2020 Jan; 125():154799. PubMed ID: 31400638
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interferon regulatory factor 7 (IRF7) represents a link between inflammation and fibrosis in the pathogenesis of systemic sclerosis.
    Wu M; Skaug B; Bi X; Mills T; Salazar G; Zhou X; Reveille J; Agarwal SK; Blackburn MR; Mayes MD; Assassi S
    Ann Rheum Dis; 2019 Nov; 78(11):1583-1591. PubMed ID: 31439591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Systemic sclerosis: Recent insight in clinical management.
    Zanatta E; Codullo V; Avouac J; Allanore Y
    Joint Bone Spine; 2020 Jul; 87(4):293-299. PubMed ID: 31568838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-13-producing CD8+ T cells mediate dermal fibrosis in patients with systemic sclerosis.
    Fuschiotti P; Larregina AT; Ho J; Feghali-Bostwick C; Medsger TA
    Arthritis Rheum; 2013 Jan; 65(1):236-46. PubMed ID: 23001877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.